Israel Lowy

Senior Vice President, Clinical Development Unit Head, Oncology · Regeneron Pharmaceuticals

Biopharmaceuticals

Israel Lowy is senior vice president and clinical development unit head for oncology at Regeneron Pharmaceuticals. He joined as a vice president in 2010 and helped shape the company’s cancer immunotherapy program, following work at Medarex and Mount Sinai.

Last reviewed: Oct 21, 2026

Israel Lowy

Senior Vice President, Clinical Development Unit Head, Oncology Regeneron Pharmaceuticals

Last Reviewed: October 21, 2026

Executive Summary

Israel Lowy is senior vice president and clinical development unit head for oncology at Regeneron Pharmaceuticals. He joined as a vice president in 2010 and helped shape the company’s cancer immunotherapy program, following work at Medarex and Mount Sinai.

Career Highlights

  • Joined Regeneron as a vice president in 2010.
  • Is identified by the company as a principal architect of its cancer immunotherapy program.
  • Previously spent eight years at Medarex.

Professional Journey

Lowy served as an assistant professor of Medicine and Microbiology at Mount Sinai School of Medicine before moving into biotechnology. He spent eight years at Medarex before joining Regeneron in 2010 as a vice president.

He now serves as senior vice president and clinical development unit head for Oncology. Regeneron identifies him as a primary architect of its cancer immunotherapy program, connecting his clinical and scientific background with the development of the company’s oncology portfolio.

His training spans biochemical sciences, medicine, biochemistry and molecular biophysics. His academic and industry career preceded the oncology development leadership he holds at Regeneron.

Education

Lowy earned an AB in biochemical sciences from Princeton University and an MD and PhD in biochemistry and molecular biophysics from Columbia University.